IMRX Stock Forecast: Immuneering Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for Immuneering Corp. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Immuneering Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (73): The business earns solid, repeatable profits on what it owns.
Revisions (22): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IMRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | HC Wainwright & Co. | Initiates | Buy | $14 |
| 20 July 2026 | Needham | Maintains | Buy | $11 → $18 |
| 8 July 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 19 May 2026 | Chardan Capital | Maintains | Buy | — |
| 9 Mar 2026 | Needham | Reiterates | Buy | — |
| 13 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 31 Oct 2025 | Leerink Partners | Initiates | Outperform | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 25 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 15 Sept 2025 | Needham | Maintains | Buy | — |
| 26 Aug 2025 | Needham | Reiterates | Buy | — |
| 14 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 18 June 2025 | Chardan Capital | Maintains | Buy | — |
| 18 June 2025 | Mizuho | Maintains | Outperform | — |
| 18 June 2025 | Needham | Reiterates | Buy | — |
| 5 June 2025 | Needham | Reiterates | Buy | — |
| 7 May 2025 | Oppenheimer | Maintains | Outperform | — |
| 6 May 2025 | Chardan Capital | Maintains | Buy | — |
| 10 Apr 2025 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IMRX.
This page is one stock. Monday covers all of them.
IMRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IMRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Immuneering Corp. returned −51.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IMRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- —
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −33.5%
- Return on assets
- −21.8%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immuneering Corp. has a market value of $218.9M and an enterprise value of $77.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$57.3M.
Diluted earnings per share, trailing twelve months: −$1.04.
Free cash flow in the twelve months to 30 June 2026: −$57.0M.
Immuneering Corp. employs 65 people.
Data provided by Twelve Data
IMRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IMRX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Immuneering Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IMRX
What is the IMRX stock price forecast for 2026-2027?
The median 12-month analyst price target for Immuneering Corp. is $16, with estimates ranging from $11 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMRX stock a buy right now?
Of the 7 analysts covering Immuneering Corp., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immuneering Corp. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMRX?
As at 21 Nov 2026, Immuneering Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (73 of 100).
Will IMRX stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $16, and Ticker Nerd's factor model ranks Immuneering Corp. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMRX stock forecast for 2030?
No analyst covering Immuneering Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $30 over the next 12 months.
How has IMRX stock performed over the past year?
Immuneering Corp. returned -51.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immuneering Corp. do?
Immuneering Corp. Class A Common Stock represents ownership in Immuneering Corporation, a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. Immuneering’s current work centers on a pipeline of drug candidates designed to address cancer through its computational drug discovery approach, including lead programs aimed at solid tumors and mutations associated with difficult-to-treat cancers.
About Immuneering Corp.
Immuneering Corp. Class A Common Stock represents ownership in Immuneering Corporation, a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. Immuneering’s current work centers on a pipeline of drug candidates designed to address cancer through its computational drug discovery approach, including lead programs aimed at solid tumors and mutations associated with difficult-to-treat cancers. The company’s research platform supports the identification and development of therapies built to interfere with cellular signaling pathways, with an emphasis on oncology applications. Immuneering also operates in computational biology and translational bioinformatics, applying its scientific platform to advance drug discovery activities. Headquartered in Cambridge, Massachusetts, Immuneering Corporation serves the biotechnology and pharmaceutical sectors through its ongoing clinical development programs and research-driven approach to cancer medicine.
CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D. · 65 employees · United States · https://immuneering.com